Rocio Rodriguez Lopez

Personal Details

First Name:	Rocio
Middle Name:
Last Name:	Rodriguez Lopez
Suffix:
RePEc Short-ID:	pro1088
	[This author has chosen not to make the email address public] The above email address does not seem to be valid anymore. Please ask Rocio Rodriguez Lopez to update the entry or send us the correct address or status for this person. Thank you.

Affiliation

Academic Unit of Health Economics
Leeds Institute of Health Sciences
University of Leeds

Leeds, United Kingdom
https://medicinehealth.leeds.ac.uk/health-economics
RePEc:edi:heleeuk (more details at EDIRC)

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Articles

1. Ros Wade & Ana Duarte & Mark Simmonds & Rocio Rodriguez-Lopez & Steven Duffy & Nerys Woolacott & Eldon Spackman, 2015. "The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Follow," PharmacoEconomics, Springer, vol. 33(5), pages 457-466, May.

   Cited by:

   1. Hedwig Blommestein & Nigel Armstrong & Steve Ryder & Sohan Deshpande & Gill Worthy & Caro Noake & Rob Riemsma & Jos Kleijnen & Johan Severens & Maiwenn Al, 2016. "Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene," PharmacoEconomics, Springer, vol. 34(1), pages 23-31, January.

2. Ros Wade & Micah Rose & Aileen Neilson & Lisa Stirk & Rocio Rodriguez-Lopez & David Bowen & Dawn Craig & Nerys Woolacott, 2013. "Ruxolitinib for the Treatment of Myelofibrosis: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 31(10), pages 841-852, October.

   Cited by:

   1. Ros Wade & Robert Hodgson & Mousumi Biswas & Melissa Harden & Nerys Woolacott, 2017. "A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence," PharmacoEconomics, Springer, vol. 35(2), pages 203-213, February.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Rocio Rodriguez Lopez should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.